FIGURE 2.

Kaplan–Meier curves for each ALK inhibitor (PFS). (a) The median PFS of crizotinib was 9.0 months (95% CI, 7.7–10.3 months). (b) The median PFS of ceritinib was 7.0 months (95% CI, 3.4–10.6 months); the median PFS of brigatinib was 10.0 months (95% CI, 6.1–13.9 months); the median PFS of alectinib was 12.0 months (95% CI, 4.7–19.3 months). (c) The median PFS of lorlatinib was 12.5 months (second‐line: 20.0 months vs. third‐ or later‐line: 5.5 months, p = 0.011). Abbreviations: ALK, anaplastic lymphoma kinase; PFS, progression‐free survival; CI, confidence interval; p‐values <0.05 were statistically significant